- Home
- CHPT vs FATE Comparison
CHPT vs FATE Comparison
Compare CHPT & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | FATE |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 125.6M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CHPT | FATE |
|---|---|---|
| Price | $10.35 | $2.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $9.25 | $4.10 |
| AVG Volume (30 Days) | ★ 3.4M | 1.2M |
| Earning Date | 06-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | $6,646,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $16.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.44 | $0.94 |
| 52 Week High | $12.61 | $3.23 |
Technical Indicators
Market Signals| Indicator | CHPT | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 74.01 | 52.88 |
| Support Level | $5.39 | $2.27 |
| Resistance Level | $10.43 | $2.55 |
| Average True Range (ATR) | 0.77 | 0.13 |
| MACD | 0.22 | 0.01 |
| Stochastic Oscillator | 93.15 | 59.04 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.